Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Fig. 2

Effect of NTP42 on haemodynamic parameters in the rat model of MCT-induced PAH. Pulmonary and cardiac haemodynamic measurements of: a. The mPAP in the ‘No MCT’, vehicle/‘MCT Only’, NTP42, Sildenafil, and Selexipag groups [n = 14, 11, 12, 12 and 6, respectively]; b. RVSP [n = 12, 13, 12, 11 and 6, respectively]; c. Fulton’s Index [n = 12, 12, 13, 12, and 6, respectively]; d. HR [n = 14,, 14, 12, 11 and 6, respectively], and (e). mAP [n = 12, 14, 13, 12 and 6, respectively] are shown for normal control rats (‘No MCT’) and rats treated with MCT (60 mg/kg, s.c) followed by treatment twice daily orally with either drug vehicle (‘MCT Only’ BID, p.o), NTP42 (0.25 mg/kg BID, p.o.), Sildenafil (50 mg/kg BID, p.o.), or Selexipag (1 mg/kg BID, p.o.) starting from the Day 1 following administration of MCT. All data are expressed as the mean ± SEM. * P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 0.0001 vs. ‘MCT Only’, according to unpaired Student’s t tests (Panels a-c) or one-way ANOVA (Panels D & E). Note that while Supplemental Table 1A provides details on numbers of animals enrolled into the study and those that survived through to terminal surgery, the numbers (n) given in the square brackets in the figure legends refer to the number of input data used for the given experimental parameter following removal of any justifiable outliers identified using the method of interquartile range (IQR) with Tukey fences

Back to article page